Skip to content Dark Web Informer - Cyber Threat Intelligence
Support
Sign In Subscribe
Initial Access

miyako is Claiming to Sell Access to an Unidentified $29.5 Billion Pharmaceutical Company

,   and  Dark Web Informer
2 min read

💡This post is part of Free Post Friday! If you're interested in subscribing to the platform please visit the subscriber page: https://darkwebinformer.com/status/#/portal/signup. If you would prefer to pay via cryptocurrency, please visit: https://darkwebinformer.com/crypto-payments

If you're interested in advertising please visit: https://darkwebinformer.com/advertising-rates/

📌 Quick Facts

🔗 DarkWebInformer.com - Cyber Threat Intelligence
📅 Date: 2025-02-28 13:46:50
🚨 Title: Alleged Access Sale to an Unidentified Pharmaceutical Company
🛡️ Victim Country: Unspecified
🏭 Victim Industry: Healthcare & Pharmaceuticals
🏢 Victim Organization: Unidentified
🌐 Victim Site: Not Provided
📜 Category: Initial Access
🔗 Claim: https://breachforums.st/Thread-29-5-billion-Revenue-Global-Pharmaceutical-Company-One-of-largest-in-the-world
🕵️‍♂️ Threat Actor: miyak000
🌍 Network: OpenWeb

📝 What Happened?
A cybercriminal identified as miyak000 has listed Remote Code Execution (RCE) access for sale, allegedly belonging to a global pharmaceutical company with $29.5 billion in annual revenue. The access is priced at $500, making it an affordable entry point for potential cybercriminals.

If legitimate, this RCE vulnerability could allow threat actors to:

  • Execute arbitrary commands on company servers, potentially leading to data exfiltration or malware deployment.
  • Compromise sensitive pharmaceutical research and intellectual property.
  • Disrupt business operations, including supply chain logistics and healthcare production.

📊 Compromised Access Details

  • RCE access to a pharmaceutical giant, enabling unauthorized control over systems.
  • $500 price tag, making it a high-risk yet affordable cybercrime opportunity.
  • Potential impact includes corporate espionage, regulatory violations, and operational disruption.

🛡 WhiteIntel.io Data Leak Information
(No victim site disclosed)

⚠ Implications

  • Intellectual Property Risks – Unauthorized access could expose proprietary drug formulations and research.
  • Regulatory Compliance Issues – Breach of pharmaceutical data may violate HIPAA, GDPR, or FDA security regulations.
  • Supply Chain Disruptions – Cybercriminals may interfere with production or distribution channels, affecting critical medicine availability.

🔧 Recommended Actions

  • Conduct Immediate Vulnerability Assessments – Identify and patch any exploitable RCE flaws.
  • Enhance System Logging & Monitoring – Detect unauthorized execution of commands on critical infrastructure.
  • Enforce Multi-Factor Authentication (MFA) – Strengthen remote access security.
  • Engage Incident Response & Cybersecurity Teams – Secure systems and mitigate potential risks proactively.

⚠ Stay vigilant. Follow DarkWebInformer.com for real-time updates on corporate cyber threats.

Related

Latest